Toll Free: 1-888-928-9744
Published: Mar, 2014 | Pages:
49 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
CytRx Corporation - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'CytRx Corporation - Product Pipeline Review - 2014', provides an overview of the CytRx Corporation's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of CytRx Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of CytRx Corporation including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of CytRx Corporation's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the CytRx Corporation's pipeline products Reasons to buy - Evaluate CytRx Corporation's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of CytRx Corporation in its therapy areas of focus - Identify new drug targets and therapeutic classes in the CytRx Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of CytRx Corporation and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of CytRx Corporation - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of CytRx Corporation and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 CytRx Corporation Snapshot 5 CytRx Corporation Overview 5 Key Information 5 Key Facts 5 CytRx Corporation - Research and Development Overview 6 Key Therapeutic Areas 6 CytRx Corporation - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 CytRx Corporation - Pipeline Products Glance 13 CytRx Corporation - Late Stage Pipeline Products 13 Phase III Products/Combination Treatment Modalities 13 CytRx Corporation - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Phase I Products/Combination Treatment Modalities 15 CytRx Corporation - Early Stage Pipeline Products 16 Preclinical Products/Combination Treatment Modalities 16 CytRx Corporation - Unknown Stage Pipeline Products 17 Unknown Products/Combination Treatment Modalities 17 CytRx Corporation - Drug Profiles 18 aldoxorubicin 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 bafetinib 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 tamibarotene 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Cyt-HiPoA 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Cyt-PLAT 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Cyt-Topo 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 CytRx Corporation - Pipeline Analysis 27 CytRx Corporation - Pipeline Products by Target 27 CytRx Corporation - Pipeline Products by Route of Administration 29 CytRx Corporation - Pipeline Products by Molecule Type 30 CytRx Corporation - Pipeline Products by Mechanism of Action 31 CytRx Corporation - Recent Pipeline Updates 33 CytRx Corporation - Dormant Projects 42 CytRx Corporation - Discontinued Pipeline Products 43 Discontinued Pipeline Product Profiles 43 INNO-305 43 tamibarotene 43 CytRx Corporation - Company Statement 44 CytRx Corporation - Locations And Subsidiaries 47 Head Office 47 Appendix 48 Methodology 48 Coverage 48 Secondary Research 48 Primary Research 48 Expert Panel Validation 48 Contact Us 49 Disclaimer 49
List of Tables CytRx Corporation, Key Information 5 CytRx Corporation, Key Facts 5 CytRx Corporation - Pipeline by Indication, 2014 8 CytRx Corporation - Pipeline by Stage of Development, 2014 9 CytRx Corporation - Monotherapy Products in Pipeline, 2014 10 CytRx Corporation - Partnered Products in Pipeline, 2014 11 CytRx Corporation - Partnered Products/ Combination Treatment Modalities, 2014 12 CytRx Corporation - Phase III, 2014 13 CytRx Corporation - Phase II, 2014 14 CytRx Corporation - Phase I, 2014 15 CytRx Corporation - Preclinical, 2014 16 CytRx Corporation - Unknown, 2014 17 CytRx Corporation - Pipeline by Target, 2014 28 CytRx Corporation - Pipeline by Route of Administration, 2014 29 CytRx Corporation - Pipeline by Molecule Type, 2014 30 CytRx Corporation - Pipeline Products by Mechanism of Action, 2014 32 CytRx Corporation - Recent Pipeline Updates, 2014 33 CytRx Corporation - Dormant Developmental Projects,2014 42 CytRx Corporation - Discontinued Pipeline Products, 2014 43
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.